The GOLGA2 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population, derived from Ca Ski cervical carcinoma cells, with targeted disruption of the GOLGA2 gene. This heterogeneous pool avoids clonal selection biases, preserving cellular diversity for robust functional studies. The editing disrupts GOLGA2 expression, creating a loss-of-function model suitable for investigating Golgi organization and trafficking in a cancer context.
The Ca Ski cell line originates from a cervical epidermoid carcinoma metastasis and is stably positive for HPV-16, expressing the viral oncoproteins E6 and E7. This background makes it a standard model for HPV-driven oncogenesis, exhibiting epithelial characteristics and dependence on viral gene expression for proliferation. The defined genetic landscape facilitates CRISPR-edited cell generation and functional analysis of host-virus interactions within cervical cancer pathways.
GOLGA2 encodes a Golgi matrix protein vital for organelle stacking and vesicular trafficking. It scaffolds interactions with GRASP65, p115/USO1, and AKAP450, and is regulated by CDK1- and PLK1-mediated phosphorylation during mitosis. The MEK/ERK cascade additionally controls GOLGA2, linking signaling to Golgi dynamics. Downstream, GOLGA2 influences MMP secretion, cell migration, and cell cycle progression through coordination with Rab GTPases and COPI/COPII/SNARE vesicle machineries. This positions GOLGA2 as a central integrator of Golgi structure and secretory function.
In HPV-16 positive Ca Ski cells, GOLGA2 knockout reveals how Golgi fragmentation impacts cervical cancer aggressiveness. Impaired MMP secretion likely reduces invasive capacity, connecting Golgi integrity to metastasis. This model is ideal for testing whether viral oncoproteins rely on GOLGA2-mediated trafficking to sustain tumor cell migration. The polyclonal knockout mimics heterogeneous tumor cell populations, enabling studies on how GOLGA2 loss alters secretory profiles and viral gene expression in a physiologically relevant cervical cancer setting.
Applications include immunofluorescence for Golgi markers (GM130, GRASP65), Western blotting for knockout validation and secretory proteins, and Transwell migration/invasion assays. ELISA quantifies secreted factors, and flow cytometry analyzes cell cycle effects. The cells also serve as a platform for drug screening targeting Golgi-mediated trafficking in cancers or neurodegenerative diseases. For further details, please contact Ascent Research.
